OxTalks is Changing
OxTalks will soon move to the new Halo platform and will become 'Oxford Events.' There will be a need for an OxTalks freeze. This was previously planned for Friday 14th November – a new date will be shared as soon as it is available (full details will be available on the Staff Gateway).
In the meantime, the OxTalks site will remain active and events will continue to be published.
If staff have any questions about the Oxford Events launch, please contact halo@digital.ox.ac.uk
Progress Towards Targeted Immunotherapy for Cancer
Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.
Their mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.
Built on proprietary ImmTAX platform, they have a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV
Date:
16 January 2025, 12:00
Venue:
Microsoft Teams
Speaker:
Dr Robert Wilkinson (Immunocore)
Organising department:
Medical Sciences Office
Organisers:
Sheena Lee (MSD Business Partnerships Office),
Medical Sciences Division Business Partnerships Office (University of Oxford)
Organiser contact email address:
sheena.lee@medsci.ox.ac.uk
Hosts:
Sheena Lee (MSD Business Partnerships Office),
Dr Charlotte Bell (University of Oxford)
Part of:
Industry Insight Seminar Series
Booking required?:
Required
Booking url:
https://forms.office.com/e/JVN7QRUkPv
Cost:
Free
Audience:
Members of the University of Oxford and the UK Biotech/Pharma industry
Editor:
Sheena Lee
